Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 9, Issue 3, 2007, Pages 223-231

  Chlup, Rudolf ^a,c   Zapletalová, Jana ^a   Sečkař, Pavel ^b   Malá, Eva ^c   Doubravová, Blanka ^c   Táncosová, Svatava ^c   Chlupová, Ludmila ^a   Pukowietz, Libor ^a   Zatloukal, Petr ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c Institute of Neurology and Geriatrics   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; MONOCOMPONENT INSULIN; NEUTRAL INSULIN; RECOMBINANT HUMAN INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL;

EID: 34250759788     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.0018     Document Type: Article

References (43)

1. Krones R, Heise T, Basir S, Klein C, Kaiser M, Sawicki PT: Time action profiles of insulin aspart and human regular insulin in middle-aged and elderly subjects with Type 2 diabetes [abstract]. Diabetologia 2004;47:A266.
2. Lindholm A, Jacobsen LV: Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-659.
3. Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J: Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2002;110:416-419.
4. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR: A direct comparison of insulin aspart and insulin lispro in patients with Type 1 diabetes. Diabetes Care 2002;25:2053-2057.
5. Standl E: Insulin analogues - state of the art. Horm Res 2002;57:40-45.
6. Bruns W: Zur Therapie des Typ-2-Diabetes - Ansätze für eine frühzeitig beginnende pathophysiologisch begründete Therapie mit Insulin. Diabetes Dialog 1998;1:9-13.
7. Chlup R, Vaverková H, Bartek J: Complementary insulin therapy improves blood glucose and serum lipids parameters in type 2 (non-insulin-dependent) diabetic patients. I. Effects on blood glucose control. Exp Clin Endocrinol Diabetes 1997;105(Suppl 2):70-73.
8. Vaverková H, Chlup R, Ficker L, Novotný D, Bartek J: Complementary insulin therapy improves blood glucose and serum lipids parameters in type 2 (non-insulin-dependent) diabetic patients. II. Effects on serum lipids, lipoproteins and apoproteins. Exp Clin Endocrinol Diabetes 1997;105(Suppl 2):74-77.
9. Fischer S, Bruns W, Kohler C, Melchert P, Gudat U, Frank M, Hanefeld M: Substitution der Frühphase der postprandialen Insulinsekretion mit Lispro bzw. Normalinsulin bei Typ-2-Diabetikern [abstract]. Diabetes Stoffwechsel 1999;8(Suppl 1):22.
10. Gerich JE: Novel insulins: expanding options in diabetes management. Am J Med 2002;113:308-316.
11. Gudat U, Kühn C, Kazda C, Lehnert H: Insulin lispro bei übergewichtigen Patienten mit Diabetes mellitus Typ 2. Diabetes Stoffwechsel 2003;12:3-7.
12. Annuzzi G, De Natale C, Bozzetto L, Patti L, Barone M, Cipriano P, Riccardi G, Rivellese AA: Effects on postprandial metabolism of insulins differing for action rapidity (aspart vs. regular) in patients with Type 2 diabetes [abstract]. Diabetologia 2004;47:A267.
13. Chapman TM, Noble S, Goa KL: Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002;62:1945-1981.
14. Gredal C, Rosenfalck A, Dejgaard A, Hilsted J: Substitution of first phase insulin response with insulin aspart in patients with newly onset type 2 diabetes [abstract]. Diabetologia 2005;48:A306.
15. Heller S: Reducing hypoglycamia with insulin analogues. Int J Obes 2002;26(Suppl):S31-S36.
16. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart. Diabetes Care 1998;21:1904-1909.
17. Pfützner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T: The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive B-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2006;8:375-384.
18. Dailey G, Rosenstock J, Moses R, Ways K: Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363-2368.
19. Chlup R, Zapletalová J, Sečkař P, Malá E, Kudlová P, Langová K: Complementary therapy with insulin aspart vs regular human insulin in persons with type 2 diabetes mellitus. [abstract]. Diabetes 2006;55(Suppl 1):A474.
20. Chlup R, Janu̇ K, Venháčová J, Bartek J: Six models of a new insulin pen (MADI): description and first clinical trial. Practical Diabetes Int 1995;12(1):32-35.
21. Bretzel RG: Intensive insulin regimens: evidence for benefit. Int J Obes 2004;(Suppl 2):58-513.
22. Kazlauskaite R, Fogelfeld L, Orlowski JM: Insulin therapy in type 2 diabetes. Dis Mon 2003;49:373-420.
23. Rotella CM, Pala L, Dicembrini I, Mannucci E: Comparison between aspart and regular insulin in combination with metformin in Type 2 diabetic patients [abstract]. Diabetologia 2004;47:A266.
24. UK Prospective Diabetes Study (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
25. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajalas S, Ryysy L, Salo S, Seppälä P, Tulokas T, Viikari J, Karjalainen J, Taskinen M-R: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-1433.
26. Ratzmann KP: Kumulative Häufigkeit des Sekundärversagens einer Sulfonylharnstoff Therapie. Diabetes Stoffwechsel 1994;3:48-352.
27. Hermansen K, Derezinski T, Kim H, Gall MA: Treatment with insulin determir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes [abstract]. Diabetologia 2004;47:A273.
28. Jain R, Braceras R, Wahl T, Wahlen J, Bressler P, Deng L, Garber A: Patients with type 2 diabetes not achieving glycemic targets on OADs with/without basal insulin can reach HbA1c targets with biphasic insulin aspart 30/70 [abstract]. Diabetologia 2005;48:A304.
29. Morozova A, Sayfullina M, Vedenieeva L, Al Tayar B, Sokolovskaya V, Tarasov A, Kazakova E: Biphasic insulin aspart 30, a premix analogue, is an effective and well-tolerated starter insulin in type 2 diabetes [abstract]. Diabetologia 2005;48:A311.
30. Raslova K, Karl D, Can Tamer S: Insulin detemir is associated with less weight gain than NPH insulin, especially in the very obese, when used in basal bolus therapy for patients with type 2 diabetes [abstract]. Diabetologia 2005;48:A306.
31. Bruns W, Fiedler H, Altmann B, Lundershausen R, Menzel R, Worms F, von Kriegstein E: Insulintherapie bei Typ 2-Diabetes. Bremen, Germany: UNI-MED Verlag AG, 2004.
32. Davies MJ, Metcalfe J, Gray JL, Day JL, Hales CN: Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type-2 diabetes mellitus. Diabet Med 1993;10:305-312.
33. Kalfhaus J, Berger M: Supplementäre Insulintherapie (SII) - wie effektiv und sicher ist die Gabe von praeprandialem Normalinsulin als Therapie-Alternative bei Typ-2-Diabetes? [abstract]. Diabetes Stoffwechsel 1999;8(Suppl 1):44.
34. Lundershausen R, Kaiser M, Haeuser C, Muenscher C, Potthoff E: Effectiveness of prandial insulin therapy for patients with Type 2 diabetes - clinical results of "PHAZIT" [abstract]. Diabetologia 2004;47:A264.
35. Ohkubo Y, Kishikawa H, Araki E, Miyata R, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progressions of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 2000;28:103-117.
36. Rolla R: The pathophysiological basis for intensive insulin replacement. Int J Obes 2004;(Suppl 2):53-57.
37. Worm F, Thiele M, Osterheld A: Insulin Glargin bei Typ-2-Diabetes. Vergleichende Untersuchung unter Einbeziehung von Fastentests. Diabetes und Stoffwechsel 2005;14:367-373.
38. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Harthi AA, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28:1568-1573.
39. Consensus statement: Recommendation for the management of patients with type 2 diabetes mellitus in the Central, Eastern and Southern European region. Int J Postgrad Train Med 2001;13:1-20.
40. Vozár J, Uličiansky V, Tkáč I, Martinka E, Michálek J, Krahulec B, Porubská M, Okapcová J: Racionálna liečba diabetes mellitus 2. typu [rationale treatment of type 2 diabetes mellitus]. Diabetes Obezita 2004;4(7):79-91.
41. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-1721.
42. Chlup R, Zapletalová J, Sečkař P, Chlupová L, Táncosová S, Řezníčková S: Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump. Biomed Papers 2004;148:27-32.
43. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart. Diabetes Care 1999;22:801-805.